SAB BIOTHERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
SAB BIOTHERAPEUTICS, INC. (SABS) reported Basic Shares Outstanding (Weighted Average) of 79.75 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 79.75M shares, a 758.07% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 53.56M shares, a 476.42% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 48.00M shares, a 416.56% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 10.66M shares, a 15.13% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 19.31M shares, a 108.51% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 9.26M shares, a 67.74% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 5.52M shares, a 26.86% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 4.35M shares, a 84.08% decline from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 79.75M shares 10-Q · filed 2026-08-06 | 66.77M shares 10-Q · filed 2026-08-06 | 60.44M shares derived: average of 3 quarters · filed 2026-08-06 | 47.99M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | 53.56M shares 10-Q · filed 2026-05-12 | 50.78M shares derived: average of 2 quarters · filed 2026-05-12 | 37.40M shares derived: average of 3 quarters · filed 2026-05-12 | 30.38M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | 48.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 29.33M shares derived: average of 2 quarters · filed 2026-03-09 | 22.65M shares derived: average of 3 quarters · filed 2026-08-06 | 19.31M shares 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 10.66M shares 10-Q · filed 2025-11-14 | 9.98M shares derived: average of 2 quarters · filed 2026-08-06 | 9.75M shares 10-Q · filed 2025-11-14 | 9.63M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | 9.29M shares 10-Q · filed 2026-08-06 | 9.29M shares 10-Q · filed 2026-08-06 | 9.29M shares derived: average of 3 quarters · filed 2026-08-06 | 9.28M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | 9.29M shares 10-Q · filed 2026-05-12 | 9.29M shares derived: average of 2 quarters · filed 2026-05-12 | 9.28M shares derived: average of 3 quarters · filed 2026-05-12 | 9.27M shares derived: average of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | 9.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 9.28M shares derived: average of 2 quarters · filed 2026-03-09 | 9.27M shares derived: average of 3 quarters · filed 2026-03-09 | 9.26M shares 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 9.26M shares 10-Q · filed 2025-11-14 | 9.26M shares derived: average of 2 quarters · filed 2025-11-14 | 9.25M shares 10-Q · filed 2025-11-14 | 8.63M shares derived: average of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | 9.26M shares 10-Q · filed 2025-08-07 | 9.25M shares 10-Q · filed 2025-08-07 | 8.42M shares derived: average of 3 quarters · filed 2025-08-07 | 7.62M shares derived: average of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | 9.24M shares 10-Q · filed 2025-05-09 | 8.00M shares derived: average of 2 quarters · filed 2025-05-09 | 7.08M shares derived: average of 3 quarters · filed 2025-05-09 | 6.57M shares derived: average of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | 6.76M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 6.00M shares derived: average of 2 quarters · filed 2025-03-31 | 5.68M shares derived: average of 3 quarters · filed 2025-03-31 | 5.52M shares 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 5.24M shares 10-Q · filed 2024-11-06 | 52.41M shares 10-Q · filed 2023-11-13 | 5.14M shares derived: average of 2 quarters · filed 2024-11-06 | 5.11M shares 10-Q · filed 2024-11-06 | 51.08M shares 10-Q · filed 2023-11-13 | -24.10M shares derived: average of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | 5.04M shares 10-Q · filed 2024-08-08 | 50.42M shares 10-Q · filed 2023-08-21 | 5.04M shares 10-Q · filed 2024-08-08 | 50.41M shares 10-Q · filed 2023-08-21 | -33.88M shares derived: average of 3 quarters · filed 2024-08-08 | -14.65M shares derived: average of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | 5.04M shares 10-Q · filed 2024-05-20 | 50.40M shares 10-Q · filed 2023-05-15 | -53.34M shares derived: average of 2 quarters · filed 2024-05-20 | -21.22M shares derived: average of 3 quarters · filed 2024-05-20 | -5.16M shares derived: average of 4 quarters · filed 2024-05-20 | |||
| 2022-12-31 | -111.72M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -34.34M shares derived: average of 2 quarters · filed 2024-03-29 | -8.56M shares derived: average of 3 quarters · filed 2024-03-29 | 4.35M shares 10-K · filed 2024-03-29 | 43.52M shares 10-K · filed 2023-04-14 | |||
| 2022-09-30 | 43.03M shares 10-Q · filed 2023-11-13 | 43.02M shares derived: average of 2 quarters · filed 2023-11-13 | 43.04M shares 10-Q · filed 2023-11-13 | 40.15M shares derived: average of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | 43.00M shares 10-Q · filed 2023-08-21 | 43.05M shares 10-Q · filed 2023-08-21 | 39.18M shares derived: average of 3 quarters · filed 2023-08-21 | 35.88M shares derived: average of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | 43.11M shares 10-Q · filed 2023-05-15 | 37.27M shares derived: average of 2 quarters · filed 2023-05-15 | 33.51M shares derived: average of 3 quarters · filed 2023-05-15 | 31.62M shares derived: average of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | 31.44M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | 28.70M shares derived: average of 2 quarters · filed 2023-04-28 | 27.79M shares derived: average of 3 quarters · filed 2023-04-28 | 27.34M shares 10-K/A · filed 2023-04-28 | ||||
| 2021-09-30 | 25.97M shares 10-Q · filed 2022-11-14 | 25.97M shares derived: average of 2 quarters · filed 2022-11-14 | 25.97M shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 25.97M shares 10-Q · filed 2022-08-10 | 25.97M shares 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | 25.97M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 25.39M shares 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |